These data are phenotypically consistent with increased Yes/phosphatidylinositol 3‐kinase (PI3K)/GSK3β/matrix metalloproteinase (MMP)-mediated migration upon pharmacologic CD95 stimulation in long-term glioma cell lines [27] and upon inhibition of exogenous CD95L-induced invasion by pharmacological CD95L neutralization [29, 30]. The gene discussed is YES1; the disease is central nervous system cancer.